Insiders Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.89 ^USD	+1.23%		-16.71%	-9.97%

Apr. 26	Allogene Therapeutics Gets $15 Million Grant from California Institute for Regenerative Medicine for Cancer Drug Development	MT
Apr. 26	Allogene Therapeutics Receives Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Allogene Therapeutics, Inc. Appoints Geoffrey Parker as Executive Vice President	23-10-16	CI
Allogene Therapeutics, Inc. Appoints Geoffrey Parker as Chief Financial Officer	23-10-16	CI
Allogene Therapeutics Finance Chief Eric Schmidt to Step Down	23-06-14	MT
Allogene Therapeutics, Inc. Announces Resignation of Eric Schmidt from Principal Financial Officer and Principal Accounting Officer, Effective from August 2, 2023	23-06-14	CI
Allogene Therapeutics, Inc. Appoints Timothy Moore as Executive Vice President and Chief Technical Officer, Effective April 24, 2023	23-04-21	CI
Allogene Therapeutics, Inc., Announces Resignation of Alison Moore as Chief Technical Officer, Effective April 28, 2023	23-04-20	CI
Allogene Therapeutics, Inc. Announces Resignation of Rafael G. Amado as Executive Vice President of Research and Development	23-01-03	CI
Allogene Appoints Zachary J. Roberts as Executive Vice President of Research & Development	23-01-03	CI
Insider Sell: Allogene Therapeutics	22-08-15	MT
Allogene Therapeutics, Inc. Appoints Scientific Pioneer Stephen Mayo to its Board of Directors	22-07-12	CI
Insider Sell: Allogene Therapeutics	22-06-23	MT
Allogene Therapeutics Named 2022 Bay Area 'Best Place to Work' by San Francisco Business Times and Silicon Valley Business Journal	22-05-10	AQ
Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business Journal	22-05-09	GL
Allogene Therapeutics, Inc. Appoints Susan Lundeen as Chief People Officer, Effective May 2, 2022	22-04-28	CI
Insider Buy: Allogene Therapeutics	22-01-14	MT
Insider Buy: Allogene Therapeutics	22-01-14	MT
Allogene Therapeutics Appoints Jae Park to Its Scientific Advisory Board	21-09-20	CI
Insider Sell: Allogene Therapeutics	21-09-17	MT
Insider Sell: Allogene Therapeutics	21-09-09	MT
Allogene Therapeutics, Inc. Announces Executive Appointments	21-08-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Insiders Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Insiders

Filters